(17078830), Q. X., (17078833), K. H., (17078836), X. M., (17078839), Y. W., (17078842), L. Z., (17078845), L. B., . . . (17078857), Q. C. (2025). Supplementary Table S3 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma.
Citación estilo Chicago(17078830), Qingsheng Xu, et al. Supplementary Table S3 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma. 2025.
Cita MLA(17078830), Qingsheng Xu, et al. Supplementary Table S3 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma. 2025.
Warning: These citations may not always be 100% accurate.